Rocket Pharmaceuticals
RCKT
146 hedge funds and large institutions have $1.85B invested in Rocket Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 55 increasing their positions, 49 reducing their positions, and 16 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 49
1.47% less ownership
Funds ownership: 97.68% → 96.21% (-1.5%)
3% less funds holding
Funds holding: 150 → 146 (-4)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
32% less capital invested
Capital invested by funds: $2.74B → $1.85B (-$888M)
Top Buyers
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$54.1M |
| 2 |
RI
RTW Investments
New York
|
+$29.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.1M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$19.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$18.2M |
Top Sellers
RCKT Hedge Fund Activity: Q3 2021 in Review
146 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2021, worth a combined $1.85B — down 32% from $2.74B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RCKT and 12 opened new positions — a net loss of 4 holders — while 49 trimmed existing stakes and 55 added.
The largest buyer was Maverick Capital, adding an estimated $54.1M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $39.8M sold.
- 146 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2021, down from 150 in Q2 2021.
- Funds reported $1.85B of Rocket Pharmaceuticals stock for Q3 2021, down 32% quarter-over-quarter.
- 12 funds opened new Rocket Pharmaceuticals positions in Q3 2021 and 16 closed out, a net change of -4 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2021 was Maverick Capital, an estimated $54.1M added.
- The largest Rocket Pharmaceuticals seller in Q3 2021 was Loomis, Sayles & Company, an estimated $39.8M sold.
Based on aggregated 13F filings for Q3 2021.